Evidence map›Paper›PMID 41308123›Full record

ArticleScience (New York, N.Y.)2026

Structural basis for the recruitment and selective phosphorylation of Akt by mTORC2.

Martin S Taylor, Maggie Chen, Matthew Hancock, Maximilian Wranik, Bryant D Miller, Timothy R O'Meara, Brad A Palanski, Scott B Ficarro, Brian J Groendyke, Yufei Xiang and 19 more

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Martin S Taylor *Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.ORCID 0000-0001-5824-142X
Maggie Chen *Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-1900-1017
Matthew Hancock *Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.
Maximilian Wranik *Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Bryant D MillerDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0009-0006-9145-8499
Timothy R O'MearaDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-3651-5167
Brad A PalanskiDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-4049-4274
Scott B FicarroDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1521-7996
Brian J GroendykeDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yufei XiangDepartment of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-6732-5649
Kazuma T KondoDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.ORCID 0009-0002-3270-278X
Karen Y Linde-GarelliDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-3438-6477
Michelle J LeeDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0009-0009-9122-335X
Dibyendu MondalDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5047-6985
Daniel FreundWhitehead Institute for Biomedical Research, Cambridge, MA, USA.ORCID 0009-0008-8739-6920
Samantha CongreveWhitehead Institute for Biomedical Research, Cambridge, MA, USA.ORCID 0009-0001-5277-2235
Kaay MatasWhitehead Institute for Biomedical Research, Cambridge, MA, USA.ORCID 0009-0004-8968-0280
Maximiliaan HenninkWhitehead Institute for Biomedical Research, Cambridge, MA, USA.ORCID 0009-0000-1589-1780
Kera XibinakuWhitehead Institute for Biomedical Research, Cambridge, MA, USA.ORCID 0009-0000-1601-5555
Max L ValensteinDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-7616-0148
Trevor van EeuwenLaboratory of Cellular and Structural Biology, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-0549-1702
Jarrod A MartoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2086-1134
Andrej SaliDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0435-6197
Yi ShiDepartment of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-2761-8324
Nathanael S GrayDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-5354-7403
David M SabatiniInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-1446-7256
Nam ChuDepartment of Cancer Biology and Genetics, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.ORCID 0000-0001-9717-5007
Kacper B RogalaDepartment of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-5997-7770
Philip A ColeDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0001-6873-7824

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI MICHAEL KENNEY · 2007 to 2026
$71.4M
Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
TR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2014 to 2023
$18.8M
Chemical Approaches to Protein PhosphorylationR01CA074305 · NCI · JOHNS HOPKINS UNIVERSITY · PI COLE, PHILIP A · 2002 to 2025
$8.0M
Regulation of the mTOR Pathway By NutrientsR01CA103866 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2004 to 2021
$7.0M
Cell Growth Signaling in Cancer DevelopmentR01CA129105 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2008 to 2021
$5.9M
IMP: Software for Hybrid Determination of Macromolecular Assembly StructuresR01GM083960 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SALI, ANDREJ · 2008 to 2024
$5.2M
TRANSLATIONAL CONTROL BY RAPAMYCIN-SENSITIVE SIGNALINGR01AI047389 · NIAID · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2000 to 2021
$4.9M
Mapping the Dynamic Interactome of Ig-fold Membrane Proteins Using Nanobody-Based ToolsR35GM137905 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Yi Shi · 2020 to 2026
$2.8M
Novel Screening Platform for Discovery of DUB Targeting ProbesR01CA233800 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2019 to 2022
$2.5M
Chemoenzymatic Protein Semisynthesis Approaches Toward Cell Signaling EnzymesR35GM151124 · NIGMS · OHIO STATE UNIVERSITY · PI Nam Ky Chu · 2023 to 2026
$1.6M
Mechanisms of amino-acid sensing by the GATOR complexR35GM150935 · NIGMS · STANFORD UNIVERSITY · PI Kacper Rogala · 2023 to 2026
$1.4M
NCI NIH HHS F32 CA259214NCI NIH HHS K22 CA241105NCI NIH HHS P30 CA124435NCI NIH HHS R00 CA255926NCI NIH HHS R01 CA074305NCI NIH HHS R01 CA103866NCI NIH HHS R01 CA129105NCI NIH HHS R01 CA233800NCI NIH HHS R21 CA261737NCI NIH HHS T32 CA009302NIAID NIH HHS R01 AI047389NIDDK NIH HHS K08 DK129824NIGMS NIH HHS P41 GM109824NIGMS NIH HHS R01 GM083960NIGMS NIH HHS R35 GM137905NIGMS NIH HHS R35 GM150935NIGMS NIH HHS R35 GM151124
6 · The paper itself

Abstract

The mechanistic target of rapamycin (mTOR) protein kinase forms two multiprotein complexes, mTORC1 and mTORC2, that function in distinct signaling pathways. mTORC1 is regulated by nutrients, and mTORC2 is a central node in phosphoinositide-3 kinase (PI3K) and small guanosine triphosphate Ras signaling networks commonly deregulated in cancer and diabetes. Although mTOR phosphorylates many substrates in vitro, in cells, mTORC1 and mTORC2 have high specificity: mTORC2 phosphorylates the protein kinases Akt and PKC, but not closely related kinases that are mTORC1 substrates. To understand how mTORC2 recognizes substrates, we created semisynthetic probes to trap the mTORC2 :: Akt complex and determine its structure. Whereas most protein kinases recognize amino acids adjacent to the phosphorylation site, local sequence contributes little to substrate recognition by mTORC2. Instead, the specificity determinants were secondary and tertiary structural elements of Akt that bound the mTORC2 component mSin1 distal to the mTOR active site and were conserved among at least 18 related substrates. These results reveal how mTORC2 recognizes its canonical substrates and may enable the design of mTORC2-specific inhibitors.

Indexed as

Mechanistic Target of Rapamycin Complex 2Proto-Oncogene Proteins c-aktAmino Acid SequenceCatalytic DomainHCT116 CellsHumansMechanistic Target of Rapamycin Complex 1PhosphorylationSubstrate SpecificityMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Proto-Oncogene Proteins c-akt

Identifiers

PMID41308123
PMCPMC12830033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.